While Lyme disease is rare in the UAE, cases can occur among travellers or expatriates returning from endemic regions such as Europe or North America. Chronic Lyme disease often involves persistent infection, inflammation, immune imbalance, and disruptions in cellular energy production
Standard antibiotic therapy may not fully address lingering symptoms such as fatigue, cognitive fog, and joint pain, which can persist long after initial treatment.
Peptide Therapy offers a science-supported, personalised, and integrative approach that may support immune balance, calm inflammation, promote tissue repair, and restore cellular energy, making it an emerging area of interest for individuals managing long-term post-infectious symptoms.
Lyme disease is caused by the bacterium Borrelia burgdorferi, typically transmitted through tick bites.
Early symptoms may include fever, rash, joint pain and fatigue.
If left untreated or partially treated, the infection can become chronic, affecting the nervous system, joints and immune function.
Even after completing antibiotics, many individuals continue to experience symptoms. This condition is often referred to as post‑treatment Lyme disease syndrome (PTLDS).
Thymosin Alpha-1 is a well-researched immune-regulating peptide.
Minutolo et al. (2023) found that TA-1 enhances T‑cell responses (cells that destroy infected cells) and helps modulate inflammatory cytokines (chemical messengers that drive inflammation) in SARS-Cov2 infection.
Thymosin Alpha-1 may rebalance immune function and reduce persistent inflammation following infection.
TA-1 provides a broad immune regulation and resilience.
Thymalin is a thymic peptide complex known for its role in immune system regulation and restoration.
Thymalin promotes differentiation and maturation of immune cells, particularly T-lymphocytes (white blood cells that coordinate immune responses), and macrophages (cells that engulf and remove pathogens and debris), enhancing cellular immunity and immunological memory as found by Khavinson et al. (2023).
Thymalin helps restore immune system integrity by improving the body’s ability to recognise and respond to pathogens, which is often compromised in chronic Lyme disease.
Thymalin also reduces systemic inflammation by regulating cytokine production.
Thymalin is ideal for patients requiring comprehensive immune system rebuilding and enhanced cellular immunity, which can accelerate recovery from persistent infections.
LL-37 is a natural antimicrobial peptide with potent immune-modulating properties.
LL-37 disrupts bacterial membranes and recruits immune cells to sites of infection, while also promoting wound healing.
Ridyard & Overhage (2021) found that LL-37 stops direct antimicrobial activity against bacteria like the Borrelia species and reduces inflammation by modulating immune cell signalling pathways.
LL-37 supports both bacterial clearance and tissue repair, which is vital for Lyme disease recovery.
This peptide offers a dual role by directly combating persistent bacterial infection and promoting healing of damaged tissues, making LL-37 a potential tool for comprehensive Lyme disease management.
Peptide | Main Mechanism | Lyme‑Related Benefit | Suitable For |
TA‑1 | Immune balancing via T-cell and cytokine modulation | Helps restore immune equilibrium & reduce inflammation | Immune dysregulation, persistent inflammation |
Thymalin | Stimulates T-cell and macrophage maturation | Restores immune competence and reduces cytokine storm | Chronic immune deficiency, inflammation |
LL-37 | Antimicrobial and immune cell recruitment | Directly attacks Borrelia and promotes tissue repair | Persistent infection, tissue damage |
These peptides are generally self-administered via subcutaneous injection (under the skin).
Dosages vary depending on protocol.
Always seek professional guidance for dosing and monitoring.
TA‑1 is used clinically in many countries for immune-related conditions.
Thymalin is used in clinical practice primarily in Eastern Europe and Russia, with growing recognition worldwide for immune support.
LL-37 used under active research for antimicrobial and immunomodulatory properties, with emerging therapeutic applications.
Disclaimer: Peptide Therapies are not listed by the UAE Ministry of Health and Prevention as an approved treatment for Lyme disease. They should only be considered under the guidance and supervision of a licensed medical professional.
Can these peptides assist during or after antibiotic treatment?
Yes. Peptide Therapy is typically used alongside antibiotics to support immune function, dampen inflammation and aid tissue repair in PTLDS.
Are there safety concerns?
When administered under medical supervision, these peptides have a good safety profile. Injection site irritation is common. Immune-regulating peptides like Thymosin Alpha-1 and Thymalin require monitoring in patients with autoimmune disorders, therefore it is essential to always consult a qualified healthcare professional before usage.
Can Thymalin and Thymosin Alpha‑1 be used together in a protocol?
Yes. Thymalin and Thymosin Alpha‑1 can be used alongside each other. Thymalin supports the development of immune cells, while Thymosin Alpha‑1 helps activate them. When thoughtfully combined under the guidance of a qualified healthcare professional, these thymic peptides may offer enhanced immune support, especially for individuals recovering from chronic infections such as Lyme disease. It is important to ensure that any protocol aligns with your unique biology and health needs.
Does LL‑37 have antibacterial effects specifically against Borrelia burgdorferi?
Yes. LL‑37 has been shown to disrupt bacterial membranes, including those of Borrelia burgdorferi. LL-37 also stimulates immune cells to respond more effectively to bacterial presence, making LL-37 a valuable peptide in managing persistent bacterial infections.
Which peptides best support immune system recovery?
Thymosin Alpha-1 and Thymalin are primarily focused on restoring immune competence and controlling inflammation.
When sourcing these peptides, it’s essential to look for:
UAE Peptides meets all of these standards, offering high-quality, research-grade peptides and a commitment to scientific integrity
Peptides such as TA‑1, Thymalin, and LL-37 offer meaningful support for immune modulation, tissue repair and metabolic restoration relevant to Lyme recovery.
Schedule a 30-minute consultation with our Peptide Therapy expert to learn more about tailoring these peptides to your individual needs.
Written by Elizabeth Sogeke, BSc Genetics, MPH
Elizabeth is a science and medical writer with a background in Genetics and Public Health. She holds a BSc in Genetics and a Master’s in Public Health (MPH), with a focus on mitochondrial science, metabolic health, and healthy aging. Over the past several years, she has worked with leading peptide research laboratories and functional medicine clinics, creating trusted, clinically-informed content that bridges the latest developments in peptide and longevity research with real-world applications.
Discount Applied Successfully!
Your savings have been added to the cart.
